| Pharmaceutical Information |
| Drug Name |
Edrophonium chloride |
| Drug ID |
BADD_D00748 |
| Description |
A rapid-onset, short-acting cholinesterase inhibitor used in cardiac arrhythmias and in the diagnosis of myasthenia gravis. It has also been used as an antidote to curare principles. |
| Indications and Usage |
For the differential diagnosis of myasthenia gravis and as an adjunct in the evaluation of treatment requirements in this disease. It may also be used for evaluating emergency treatment in myasthenic crises. |
| Marketing Status |
approved |
| ATC Code |
V04CX07 |
| DrugBank ID |
DB01010
|
| KEGG ID |
D00994
|
| MeSH ID |
D004491
|
| PubChem ID |
8307
|
| TTD Drug ID |
D0S5LH
|
| NDC Product Code |
49812-0011 |
| UNII |
QO611KSM5P
|
| Synonyms |
Edrophonium | Edroponium | Edrophonium Chloride | Chloride, Edrophonium | Tensilon | Edrophonium Bromide | Bromide, Edrophonium |
|
| Chemical Information |
| Molecular Formula |
C10H16ClNO |
| CAS Registry Number |
116-38-1 |
| SMILES |
CC[N+](C)(C)C1=CC(=CC=C1)O.[Cl-] |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
|
|
|
